LISDEXAMFETAMINE DIMESYLATE - Generic Drug Details

What are the generic drug sources for lisdexamfetamine dimesylate and what is the scope of freedom to operate?

Lisdexamfetamine dimesylate is the generic ingredient in three branded drugs marketed by Actavis Elizabeth, Alkem Labs Ltd, Amneal, Apotex, Ascent Pharms Inc, Elite Labs Inc, Granules, Hikma, Lannett Co Inc, Mylan, Norwich, Prinston Inc, Rhodes Pharms, Sandoz, Specgx Llc, Sun Pharm Inds Inc, Takeda Pharms Usa, Azurity, MSN, and Teva Pharms, and is included in twenty-five NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Lisdexamfetamine dimesylate has seventeen patent family members in sixteen countries.

Twenty-one suppliers are listed for this compound.

Summary for LISDEXAMFETAMINE DIMESYLATE

International Patents:	17
US Patents:	2
Tradenames:	3
Applicants:	20
NDAs:	25
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	20
Clinical Trials:	46
Patent Applications:	463
Drug Prices:	Drug price trends for LISDEXAMFETAMINE DIMESYLATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LISDEXAMFETAMINE DIMESYLATE
What excipients (inactive ingredients) are in LISDEXAMFETAMINE DIMESYLATE?	LISDEXAMFETAMINE DIMESYLATE excipients list
DailyMed Link:	LISDEXAMFETAMINE DIMESYLATE at DailyMed

See drug prices for LISDEXAMFETAMINE DIMESYLATE

Recent Clinical Trials for LISDEXAMFETAMINE DIMESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins University	PHASE2
Eli Lilly and Company	PHASE2
Humanis Saglk Anonim Sirketi	PHASE1

See all LISDEXAMFETAMINE DIMESYLATE clinical trials

Pharmacology for LISDEXAMFETAMINE DIMESYLATE

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Medical Subject Heading (MeSH) Categories for LISDEXAMFETAMINE DIMESYLATE

Central Nervous System Stimulants

Dopamine Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LISDEXAMFETAMINE DIMESYLATE

N06BA	Centrally acting sympathomimetics
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

N06BA	Centrally acting sympathomimetics
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

N06BA	Centrally acting sympathomimetics
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for LISDEXAMFETAMINE DIMESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VYVANSE	Capsules	lisdexamfetamine dimesylate	10 mg	021977	1	2020-04-09
VYVANSE	Capsules	lisdexamfetamine dimesylate	20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg	021977	6	2011-02-23

US Patents and Regulatory Information for LISDEXAMFETAMINE DIMESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granules	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	218987-004	Jan 29, 2025	AB	RX	No	No
Sun Pharm Inds Inc	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	TABLET, CHEWABLE;ORAL	214134-006	Aug 25, 2023	AB	RX	No	No
Apotex	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	216944-001	Aug 25, 2023	AB	RX	No	No
Specgx Llc	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	211840-004	Aug 25, 2023	AB	RX	No	No
Lannett Co Inc	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	215802-003	Aug 25, 2023	AB	RX	No	No
Sandoz	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	202836-006	Jul 26, 2024	AB	RX	No	No

International Patents for LISDEXAMFETAMINE DIMESYLATE

Country	Patent Number	Title	Estimated Expiration
Mexico	2022008191	SOLUCIONES ORALES QUE COMPRENDEN SALES DE LISDEXANFETAMINA. (ORAL SOLUTIONS COMPRISING LISDEXAMFETAMINE SALTS.)
Australia	2020416052	Oral solutions comprising lisdexamfetamine salts
Israel	294249	תמיסות למתן דרך הפה המכילות מלחי ליזדקסאמפטאמין (Oral solutions comprising lisdexamfetamine salts)
European Patent Office	4098248	SOLUTIONS ORALES COMPRENANT DES SELS DE LISDEXAMFÉTAMINE (ORAL SOLUTIONS COMPRISING LISDEXAMFETAMINE SALTS)
Spain	2929192
Chile	2022001792	Soluciones orales que comprenden sales de lisdexanfetamina

Supplementary Protection Certificates for LISDEXAMFETAMINE DIMESYLATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1644019	122013000079	Germany		PRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; REGISTRATION NO/DATE: 86155.00.00 86156.00.00 86157.00.00 20130318; FIRST REGISTRATION: UK PL 08081/0050-2 20130201
1644019	301019	Netherlands		PRODUCT NAME: LISDEXAMFETAMINE, DESGEWENST IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDEZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 124498 20190528; FIRST REGISTRATION: GB PL 08081/0050-52 20130201
1644019	2020C/543	Belgium		PRODUCT NAME: LISDEXAMFETAMINE, OPTIONEEL IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDE-ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE562026, BE562035, BE562044, BE562053, BE562062, BE562071 20200520
1644019	LUC00189	Luxembourg		PRODUCT NAME: LISDEXAMFETAMINE, OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; AUTHORISATION NUMBER AND DATE: PL08081/0050-52 20200901
1644019	2013/038	Ireland		PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY A MESYLATE SALT; NAT REGISTRATION NO/DATE: PA0689/006/001 PA0689/006/002
1644019	SPC/GB13/052	United Kingdom		PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; REGISTERED: UK PL08081/0050-2 20130201; UK PL08081/0062-4 20130201

Lisdexamfetamine Dimesylate: Patent Landscape and Market Projections

Last updated: February 19, 2026

Lisdexamfetamine dimesylate, marketed as Vyvanse by Takeda Pharmaceuticals and Shire (prior to acquisition), is a prodrug stimulant used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and binge-eating disorder (BED). Its therapeutic efficacy is linked to its conversion to dextroamphetamine in the body, a process that slows absorption and extends its duration of action. This pharmacokinetic profile has been a key factor in its market performance and patent strategy. The drug's patent exclusivity has been a significant driver of its revenue, with recent patent expiries and upcoming legal challenges shaping its future market dynamics.

What is the Current Patent Status of Lisdexamfetamine Dimesylate?

The primary U.S. patent for lisdexamfetamine dimesylate (U.S. Patent No. 7,790,717) expired on February 16, 2023. This patent covered the composition of matter for lisdexamfetamine. Additional patents relating to its manufacturing processes and methods of use also exist and have varying expiration dates.

• Composition of Matter Patent (U.S. Patent No. 7,790,717):

  • Filed: May 11, 2004
  • Granted: September 5, 2000
  • Expiration: February 16, 2023
  • Status: Expired

• Manufacturing Process Patents: Several patents cover specific synthesis routes. For example, U.S. Patent No. 9,102,575, covering a purification method, is set to expire on July 10, 2029. Another, U.S. Patent No. 10,214,637, related to polymorphic forms, expires on January 2, 2035.

• Method of Use Patents: Patents covering the treatment of BED (e.g., U.S. Patent No. 8,299,094) expire on August 6, 2027.

The expiration of the core composition of matter patent opened the door for generic manufacturers to enter the market. This has led to significant price competition and a projected decrease in revenue for the originator.

What are the Key Market Drivers for Lisdexamfetamine Dimesylate?

The market for lisdexamfetamine dimesylate has been driven by several factors, including the increasing prevalence of ADHD and BED diagnoses, the drug's perceived efficacy and favorable safety profile compared to some older stimulants, and the brand loyalty established by Takeda.

• ADHD Prevalence: Global diagnoses of ADHD have been on an upward trend, fueled by increased awareness, improved diagnostic tools, and reduced stigma. The Centers for Disease Control and Prevention (CDC) reported in 2022 that approximately 9.8% of children aged 3-17 years had ever received an ADHD diagnosis [1]. This represents a substantial patient pool seeking effective treatment.

• Binge-Eating Disorder (BED) Indication: The FDA approval of Vyvanse for BED in 2015 expanded its market reach beyond ADHD, tapping into a less-served but significant patient population. BED affects an estimated 2.8% of adults in the United States [2].

• Pharmacokinetic Profile: Lisdexamfetamine's prodrug design means it is converted to dextroamphetamine in the gastrointestinal tract and is not orally bioavailable until after absorption. This controlled release mechanism is associated with a lower abuse potential compared to immediate-release amphetamines, a key selling point for prescribers and patients concerned about misuse.

• Brand Recognition and Loyalty: As a leading branded medication for ADHD, Vyvanse has established strong brand recognition and physician trust. This brand equity is a significant asset, though its influence diminishes with the introduction of generics.

• Payer Coverage and Formulary Placement: Favorable reimbursement policies and placement on insurance formularies have historically supported Vyvanse's market penetration. However, generic entry typically triggers formulary adjustments to favor lower-cost alternatives.

What is the Historical Financial Performance of Lisdexamfetamine Dimesylate?

Lisdexamfetamine dimesylate has been a significant revenue generator for Shire and later Takeda. Its peak sales reflect its market dominance in ADHD treatment.

• Takeda's Fiscal Year 2022 Sales: Vyvanse reported $3.03 billion in net sales for Takeda's fiscal year ending March 31, 2023 [3]. This represented a substantial portion of Takeda's overall revenue.
• Shire's Performance Prior to Acquisition: Before Takeda acquired Shire in 2019 for approximately $62 billion, Shire's specialty medicines division, heavily reliant on Vyvanse, demonstrated robust growth. In 2018, Vyvanse sales reached approximately $2.4 billion [4].
• Growth Trajectory: From its U.S. launch in 2007, Vyvanse experienced consistent year-over-year sales growth driven by expanding indications and market penetration.

The significant revenue figures highlight the drug's commercial success during its patent-protected period. The expiration of key patents is expected to lead to a sharp decline in branded sales as generics capture market share.

What are the Competitive Landscape and Future Market Projections?

The competitive landscape for lisdexamfetamine dimesylate is evolving rapidly due to the expiration of its primary patents. The market will now see increased competition from generic versions, impacting pricing and market share.

• Generic Entry: Following the patent expiry in February 2023, generic versions of lisdexamfetamine dimesylate have been launched by multiple pharmaceutical companies, including Teva Pharmaceuticals, Aurobindo Pharma, and others. This direct competition is driving down prices.
• Existing Stimulant Market: The ADHD market is crowded with established stimulant medications, including:
  • Methylphenidate-based products: Concerta, Ritalin, Daytrana
  • Amphetamine-based products: Adderall XR, Adzenys XR-ODT, Dexedrine
  • Non-stimulant options: Strattera, Intuniv
• Newer Formulations and Combination Therapies: The market continues to see innovation in drug delivery systems and combination therapies, presenting ongoing competition.
• Market Share Erosion: Branded Vyvanse is projected to experience a significant decline in market share and revenue as generics gain traction. Industry analysts forecast a drop of over 70% in branded Vyvanse sales within two years of generic entry.
• Projected Market Size: While specific projections for lisdexamfetamine dimesylate post-generic entry are dynamic, the overall ADHD market is expected to continue growing at a CAGR of 5-7% due to increasing diagnoses and global access. Generic lisdexamfetamine will capture a portion of this growth, but at significantly lower price points.
• Legal Challenges: Ongoing litigation related to secondary patents and market exclusivity strategies by the originator could influence the timing and extent of generic penetration. For instance, Takeda has faced patent litigation challenging its method-of-use patents.

The future market for lisdexamfetamine dimesylate will be characterized by high-volume, low-margin sales driven by generic manufacturers, while the branded product's market share will contract considerably.

What are the Implications of Patent Expiries and Generic Competition?

The patent expiries for lisdexamfetamine dimesylate have direct and substantial implications for Takeda and the broader pharmaceutical market.

• Revenue Loss for Originator: Takeda will face a significant reduction in revenue from Vyvanse. The loss of market exclusivity for a blockbuster drug necessitates strategic adjustments in R&D investment, pipeline prioritization, and market focus.
• Price Decreases: Generic competition inevitably leads to substantial price reductions. The average selling price (ASP) for lisdexamfetamine dimesylate is expected to decrease by 50-80% within months of generic launch, depending on the number of generic players and market dynamics.
• Increased Patient Access: Lower generic prices can improve patient access to treatment, particularly for individuals with high co-pays or those who are uninsured. This can expand the overall utilization of lisdexamfetamine dimesylate.
• Shifting Manufacturer Landscape: The market will shift from a single branded supplier to a fragmented generic market with multiple manufacturers competing on price and distribution.
• Regulatory Scrutiny: The U.S. Federal Trade Commission (FTC) monitors anti-competitive practices related to patent settlements and pay-for-delay agreements, which can impact the timing and nature of generic entry.
• Impact on R&D Investment: The revenue generated by patent-protected drugs like Vyvanse funds further R&D. The loss of such revenue can influence future investment decisions in drug development.

The implications are clear: a shift from a high-margin, single-source revenue stream to a high-volume, lower-margin, competitive market.

What are the Regulatory Considerations and Remaining Exclusivities?

While the primary composition of matter patent has expired, remaining regulatory exclusivities and secondary patents can still influence the market for lisdexamfetamine dimesylate.

• Orphan Drug Exclusivity (ODE): Lisdexamfetamine dimesylate received Orphan Drug Exclusivity for the treatment of BED. This exclusivity typically lasts for 7 years from the date of approval for the orphan indication. The BED indication was approved in December 2015, meaning this exclusivity would have expired around December 2022. However, the overlap with the general patent expiry and the nature of the indication meant this did not prevent generic entry for ADHD.
• New Chemical Entity (NCE) Exclusivity: This is typically 5 years from the date of approval. Lisdexamfetamine dimesylate received NCE exclusivity upon its initial FDA approval.
• Pediatric Exclusivity: Under the Pediatric Research Equity Act (PREA), companies may receive an additional 6 months of market exclusivity if they conduct studies in pediatric populations as required by the FDA. Information on whether this was applied and its expiration date is proprietary to Takeda.
• Secondary Patents: As noted, patents covering manufacturing processes, polymorphic forms, and specific methods of use can provide additional layers of protection, although their strength and enforceability against generic challenges vary. Litigation over these patents is common and can delay or prevent generic market entry.
• ANDA Filings: The U.S. Food and Drug Administration (FDA) approves Abbreviated New Drug Applications (ANDAs) for generic drugs. The FDA's Orange Book lists patents and exclusivities associated with approved drugs. Companies can file ANDAs once they believe the relevant patents have expired or are invalid.

The regulatory landscape is complex, with multiple layers of protection. The expiry of the primary patent was the most significant event, but the interplay of other exclusivities and patents can still shape the competitive dynamics.

Key Takeaways

• The core U.S. patent for lisdexamfetamine dimesylate (Vyvanse) expired on February 16, 2023, allowing generic manufacturers to enter the market.
• The drug has been a significant revenue generator, with Takeda reporting $3.03 billion in sales in FY2022.
• Market drivers include increasing ADHD and BED diagnoses, the drug's pharmacokinetic profile, and established brand recognition.
• Generic entry is projected to lead to a substantial decline in branded Vyvanse sales and significant price reductions.
• While the primary patent has expired, secondary patents and regulatory exclusivities may still influence market dynamics.

Frequently Asked Questions

1. When did the main U.S. patent for Vyvanse expire? The primary U.S. patent for lisdexamfetamine dimesylate, covering the composition of matter, expired on February 16, 2023.

2. Which companies are launching generic versions of lisdexamfetamine dimesylate? Several companies, including Teva Pharmaceuticals and Aurobindo Pharma, have launched or are expected to launch generic versions.

3. What is the expected impact of generic competition on the price of lisdexamfetamine dimesylate? Significant price decreases are expected, potentially ranging from 50% to 80%, as multiple generic manufacturers compete.

4. Beyond ADHD, what other condition is lisdexamfetamine dimesylate approved to treat? Lisdexamfetamine dimesylate is also approved for the treatment of binge-eating disorder (BED).

5. Can Takeda still file lawsuits to block generic entry? Takeda may pursue litigation against generic manufacturers based on remaining secondary patents related to manufacturing processes or methods of use, but the success and impact of such suits can vary.

Citations

[1] Centers for Disease Control and Prevention. (2022). Attention-Deficit/Hyperactivity Disorder (ADHD) - Data & Statistics. https://www.cdc.gov/ncbddd/adhd/data.html

[2] National Institute of Mental Health. (n.d.). Eating Disorders. Retrieved from https://www.nimh.nih.gov/health/statistics/eating-disorders

[3] Takeda Pharmaceutical Company Limited. (2023). Takeda Reports FY2022 Results. https://www.takeda.com/investors/financial-reports/fy2022/

[4] Shire plc. (2019). Shire Reports Full Year 2018 Results. https://www.shire.com/newsroom/2019/february/shire-reports-full-year-2018-results